-+ 0.00%
-+ 0.00%
-+ 0.00%
INOVIO Submits Conditional Marketing Authorization Application To EMA For VOCERYQ In Adults with Recurrent Respiratory Papillomatosis
Share
Listen to the news
  • VOCERYQ™, the first FDA-approved plasmid DNA-based immunotherapy, received FDA accelerated approval on October 30, 2026
  • Recurrent Respiratory Papillomatosis (RRP) is a rare, debilitating HPV-related disease with high unmet need in Europe
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending